National Marrow Donor Program–Sponsored Multicenter, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation Using Post-Transplant Cyclophosphamide

Study (n=50) found post-transplant cyclophosphamide in addition to standard treatment for people with a mismatched donor resulted in and overall survival of 76% at 1 year. Authors highlight results might demonstrate this is a feasible treatment to expand access to transplant.

Journal of Clinical Oncology